# Canada Chemicals Export Opportunities (HS 28-38) ![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp) > Yugalinks sector export playbook Explore Canada HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities. ## Overview - Exporter: Canada (CAN) - Sector: Chemicals - HS chapters: HS 28-38 - Latest trade year: 2024 - Sector exports: $10.1B - Products: 45 - Buyer markets: 28 - Average CAGR: +8.8% - Global sector size: $761.9B ## Product portfolio | Product | Global size | Your exports | Opportunity | CAGR | Markets | Share | | --- | ---: | ---: | ---: | ---: | ---: | ---: | | HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $286.2B | $7.4B | $97.4B | +13.9% | 17 | +1.6% | | HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $157.2B | $71.1M | $65.4B | +6.2% | 14 | +0.0% | | HS 293719 - Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: other than somatotropin, (its derivatives and structural anaologues) and insulin and its salts | $29.9B | $271.6M | $47.4B | +33.2% | 4 | +0.7% | | HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $28.6B | $8.9M | $33.3B | +25.5% | 4 | +0.0% | | HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $19.4B | $16.7M | $23.0B | +5.4% | 3 | +0.1% | | HS 300220 - Vaccines: for human medicine | $27.3B | $448.3M | $22.2B | +5.6% | 6 | +0.7% | | HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $15.4B | $2.3M | $15.5B | +11.7% | 2 | +0.0% | | HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $26.4B | $169.4M | $14.7B | +15.3% | 5 | +0.5% | | HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $24.4B | $377.8M | $14.2B | +10.6% | 7 | +0.7% | | HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $19.9B | $419.1M | $12.9B | +29.6% | 5 | +1.2% | | HS 284190 - Salts of oxometallic or peroxometallic acids: n.e.c. in heading no. 2841 | $6.6B | $8.5M | $9.7B | +11.1% | 4 | +0.1% | | HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $6.8B | $52.2M | $9.5B | +7.4% | 2 | +0.6% | | HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $11.9B | $13.7M | $7.4B | +0.8% | 2 | +0.1% | | HS 300339 - Medicaments: containing hormones (excluding insulin), (but not containing antibiotics), for therapeutic or prophylactic uses, not packaged for retail sale | $3.4B | $338.1K | $6.7B | +11.5% | 1 | +0.0% | | HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $4.7B | $29.0M | $6.0B | +10.1% | 3 | +0.5% | | HS 284410 - Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $4.1B | $105.7M | $5.5B | -11.3% | 2 | +3.9% | | HS 293319 - Heterocyclic compounds: with nitrogen hetero-atom(s) only, containing an unfused pyrazole ring (whether or not hydrogenated) in the structure, other than henazone (antipyrin) and its derivatives | $2.6B | $7.9K | $5.1B | +62.9% | 1 | +0.0% | | HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $6.9B | $1.7M | $5.1B | +10.6% | 2 | +0.0% | | HS 293379 - Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | $4.2B | $342.9K | $4.8B | +23.7% | 1 | +0.0% | | HS 282200 - Cobalt oxides and hydroxides: commercial cobalt oxides | $2.4B | $45.4K | $4.6B | +10.4% | 1 | +0.0% | | HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $8.9B | $86.6M | $4.6B | +20.9% | 2 | +1.0% | | HS 290919 - Ethers: acyclic, and their halogenated, sulphonated, nitrated or nitrosated derivatives, other than diethyl ether | $3.0B | $3.1K | $4.4B | -5.5% | 2 | +0.0% | | HS 330300 - Perfumes and toilet waters | $6.6B | $58.9M | $4.0B | +11.7% | 2 | +0.6% | | HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $9.7B | $101.2M | $3.9B | +41.4% | 1 | +1.0% | | HS 290110 - Acyclic hydrocarbons: saturated | $2.0B | $684.6 | $3.8B | +18.6% | 1 | +0.0% | | HS 283691 - Carbonates: lithium carbonate | $2.5B | $2.5 | $3.8B | -24.2% | 1 | +0.0% | | HS 381800 - Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $3.8B | $28.8K | $3.6B | -14.4% | 2 | +0.0% | | HS 290220 - Cyclic hydrocarbons: benzene | $4.1B | $2.4K | $3.5B | -68.1% | 1 | +0.0% | | HS 282520 - Lithium oxide and hydroxide | $1.6B | $1.6K | $2.7B | -0.8% | 1 | +0.0% | | HS 290121 - Acyclic hydrocarbons: unsaturated, ethylene | $1.8B | $26.8K | $2.4B | +18.9% | 1 | +0.0% | | HS 282590 - Inorganic bases, metal oxides, hydroxides and peroxides: n.e.s. in heading no. 2825 | $1.5B | $692.9 | $2.4B | -11.1% | 1 | +0.0% | | HS 285390 - Phosphides, chemically defined or not, not ferrophosphorus: other inorganic compounds n.e.c. (including distilled, conductivity water and water of like purity): liquid air, rare gases removed or not: compressed air: amalgams, not precious metal amalgams | $1.3B | $1.7M | $2.4B | +8.6% | 1 | +0.1% | | HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $3.1B | $12.7M | $2.1B | +4.2% | 1 | +0.4% | | HS 293299 - Heterocyclic compounds: with oxygen hetero-atom(s) only, no lactones or unfused furan rings (hydrogenated or not) in the structure, other than isosafrole, 1-(1,3-benzodiaxol-5-yl) propan-2-one, piperonal, safrole, tetrahydrocannabinols (all isomers) | $2.4B | $9.6M | $1.9B | +12.8% | 1 | +0.4% | | HS 382319 - Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | $1.3B | $573.6K | $1.9B | +27.7% | 1 | +0.0% | | HS 370790 - Photographic goods: chemical preparations other than sensitised emulsions, put up in measured portions or put up for retail sale in a form ready for use | $2.2B | $15.7K | $1.8B | +0.9% | 1 | +0.0% | | HS 380893 - Herbicides, anti-sprouting products and plant-growth regulators: not containing substances of 3808.50: put up in forms or packings for retail sale or as preparations or articles | $2.0B | $1.6K | $1.7B | -20.0% | 1 | +0.0% | | HS 284420 - Uranium: enriched in U235, plutonium, their compounds, alloys dispersions (including cermets), ceramic products and mixtures containing uranium enriched in U235, plutonium or compounds of these products | $4.9B | $21.1K | $1.7B | -14.4% | 1 | +0.0% | | HS 284390 - Inorganic or organic compounds: of precious metals (excluding gold and silver), whether or not chemically defined, amalgams of precious metals | $892.9M | $828.5 | $1.7B | -8.7% | 1 | +0.0% | | HS 290531 - Alcohols: acyclic, diols: ethylene glycol (ethanediol) | $3.2B | $472.8M | $1.6B | +9.7% | 1 | +14.6% | | HS 281820 - Aluminium oxide: other than artificial corundum | $1.3B | $391.9 | $1.6B | -4.4% | 1 | +0.0% | | HS 284690 - Compounds, inorganic or organic (excluding cerium), of rare-earth metals, of yttrium, scandium or of mixtures of these metals | $1.4B | $43.1K | $1.5B | +1.4% | 1 | +0.0% | | HS 293219 - Heterocyclic compounds: with oxygen hetero-atom(s) only, containing an unfused furan ring (whether or not hydrogenated) in the structure, n.e.c. in item no. 2932.1 | $990.6M | $19.3 | $1.5B | -57.5% | 1 | +0.0% | | HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $12.3 | $1.4B | -31.2% | 1 | +0.0% | | HS 291736 - Acids: aromatic polycarboxylic acids: terephthalic acid and its salts | $1.6B | $1.4K | $1.4B | -46.7% | 1 | +0.0% | ## Best markets - USA, Puerto Rico and US Virgin Islands (USA): $135.1B calculated opportunity across 16 products. - China (CHN): $56.6B calculated opportunity across 19 products. - Slovenia (SVN): $42.8B calculated opportunity across 6 products. - Germany (DEU): $41.2B calculated opportunity across 13 products. - Switzerland, Liechtenstein (CHE): $36.4B calculated opportunity across 4 products. - Belgium (BEL): $25.9B calculated opportunity across 4 products. - Italy (ITA): $23.0B calculated opportunity across 4 products. - Netherlands (NLD): $19.6B calculated opportunity across 5 products. - United Kingdom (GBR): $10.9B calculated opportunity across 5 products. - Republic of Korea (KOR): $10.9B calculated opportunity across 5 products. - Japan (JPN): $10.4B calculated opportunity across 4 products. - Spain (ESP): $7.8B calculated opportunity across 3 products. ## Growth stars - HS 293319: +62.9% average CAGR, $5.1B calculated opportunity. - HS 330499: +41.4% average CAGR, $3.9B calculated opportunity. - HS 293719: +33.2% average CAGR, $47.4B calculated opportunity. - HS 382499: +29.6% average CAGR, $12.9B calculated opportunity. - HS 382319: +27.7% average CAGR, $1.9B calculated opportunity. - HS 300214: +25.5% average CAGR, $33.3B calculated opportunity. - HS 293379: +23.7% average CAGR, $4.8B calculated opportunity. - HS 382200: +20.9% average CAGR, $4.6B calculated opportunity. - HS 290121: +18.9% average CAGR, $2.4B calculated opportunity. - HS 290110: +18.6% average CAGR, $3.8B calculated opportunity. ## Diversification opportunities - HS 300490: 17 buyer markets, $97.4B calculated opportunity. - HS 300215: 14 buyer markets, $65.4B calculated opportunity. - HS 300439: 7 buyer markets, $14.2B calculated opportunity. - HS 300220: 6 buyer markets, $22.2B calculated opportunity. - HS 300212: 5 buyer markets, $14.7B calculated opportunity. - HS 382499: 5 buyer markets, $12.9B calculated opportunity. - HS 293719: 4 buyer markets, $47.4B calculated opportunity. - HS 300214: 4 buyer markets, $33.3B calculated opportunity. - HS 284190: 4 buyer markets, $9.7B calculated opportunity. - HS 293359: 3 buyer markets, $23.0B calculated opportunity. ## Method Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology). ## Data sources - Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/) - CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf) This page presents derived Yugalinks views of reported observations and calculated indicators.